Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 2.94% 52.50 52.00 53.00 52.50 51.50 51.50 59,677 09:03:41
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -1.9 -2.3 - 45

OptiBiotix Health PLC LPLDL® Pharmaceutical GMP process validation

09/10/2019 7:00am

UK Regulatory (RNS & others)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart

2 Months : From Sep 2019 to Nov 2019

Click Here for more Optibiotix Health Charts.


RNS Number : 1911P

OptiBiotix Health PLC

09 October 2019

OptiBiotix Health plc

("OptiBiotix" or the "Company")

LP(LDL) (R) Pharmaceutical GMP process validation

Confirmation of GRAS letter received from FDA

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has completed process validation under Pharmaceutical Good Manufacturing Practices ("GMP") for LP(LDL) (R) as a drug substance and received a letter from the United States Food and Drug Administration (FDA) affirming LP(LDL) (R)'s Generally Recognized As Safe ("GRAS") status. Obtaining GMP certification is linked to a milestone payment under the pharmaceutical deal in the US (RNS: 4 September 2018,

Completing process validation under Pharmaceutical GMP's proves that a drug substance (LP(LDL) (R)) is produced consistently with pharmaceutical grade quality. GMP process validation is required by customers and health authorities around the globe to commercialise active ingredients as drugs. The validation of LP(LDL) (R) Pharmaceutical GMP manufacture is a significant step in the development of LP(LDL) (R) as a pharmaceutical drug product.

GRAS is an FDA designation that a substance added to food is considered safe. ProBiotix had obtained a positive opinion from an independent panel of experts earlier this year (RNS: 21 February 2019,, and has now received a letter from the FDA affirming LP(LDL) (R)'s status as GRAS. This is the highest level of safety certification for a food ingredient in the US and ends an almost three year scientific and regulatory process. LP(LDL) (R) (referred to as Lactobacillus plantarum ECGC 13110402, its scientific name) has been assigned the code GRN 000847 in the FDA register.

Steve Prescott, Chief Executive Officer of ProBiotix, commented: "Completing Pharmaceutical GMP process validation and receiving the GRAS notification letter from the US FDA is a significant achievement for ProBiotix and LP(LDL) (R). Few marketed probiotics have achieved this level of proven safety and efficacy and it has triggered another milestone payment in the US Pharmaceutical agreement we announced last year. GMP manufacturing is required to commercialise a probiotic as a drug and is a de facto requirement of many companies to include ingredients in their food supplement formulations. Both GMP manufacturing and full GRAS status increases LP(LDL) (R)'s market attractiveness and shows ProBiotix's commitment to commercialising the highest quality products. I would like to especially thank Dr. Luis Gosalbez who led both processes internally."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 OptiBiotix Health plc                         
 Stephen O'Hara, Chief Executive                      Contact via Walbrook 
 Cairn Financial Advisers LLP (NOMAD) 
 Liam Murray / Jo Turner / Ludovico Lazzaretti          Tel: 020 7213 0880 
   finnCap (Broker) 
 Geoff Nash / Kate Bannatyne (Corporate Finance) 
  Camille Gochez (Corporate Broking)                    Tel: 020 7220 0500 
                                                        Tel: 020 3859 7725 
   Goetz Partner Securities Limited 
   Ulrich Kinzel 
   Walbrook PR Ltd 
 Anna Dunphy                                            Mob: 07876 741 001 

About OptiBiotix -

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

October 09, 2019 02:00 ET (06:00 GMT)

1 Year Optibiotix Health Chart

1 Year Optibiotix Health Chart

1 Month Optibiotix Health Chart

1 Month Optibiotix Health Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191119 10:10:09